HLA-A1 (C57BL/6)

Taconic Terms and Conditions
HLA-A1 (C57BL/6)
  • Live
  • Mouse
  • Male & Female Available
  • Black
  • Available for direct purchase by CRO
  • Taconic Transgenic Model
Model No.NomenclatureGenotype
8909-FC57BL/6NTac-Tg(HLA-A*0101/H2-Kb)A1.01tg/wt
8909-MC57BL/6NTac-Tg(HLA-A*0101/H2-Kb)A1.01tg/wt

This model is produced upon order, with a minimum lead time of 8-12 weeks from order

Taconic Terms and Conditions
View:
Select One

Overview

Nomenclature: C57BL/6NTac-Tg(HLA-A*0101/H2-Kb)A1.01

  • Carries a transgene consisting of fragments of the human HLA-A*0101 gene and mouse H2-Kb gene which encodes a chimeric class I molecule consisting of the human HLA-A1 leader, α1 and α2 domains ligated to the murine α3, transmembrane and cytoplasmic H2-Kb domains.
  • Expresses the chimeric HLA-A1 class I molecule on the surface of T and B cells.
  • Represents the human HLA-A1 supertype.
  • Useful for infectious disease research, vaccine development and testing, safety and immunogenicity testing as well as research directed towards oncology and autoimmune disorders and syngeneic tumor studies utilizing C57BL/6-derived tumors.
  • Permits identification of epitopes restricted to the HLA-A1 supertype.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin

The HLA-A1 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the genomic clone of the human HLA-A*0101 gene that included the leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains, all under the control of the murine H2-Kb promoter. This transgene was microinjected into C57BL/6 zygotes. The resultant mice from Founder Line A1.01 were on an inbred C57BL/6 background. The line was maintained by breeding hemizygotes to wild type C57BL/6NTac mice for 10 generations. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived by breeding C57BL/6NTac wild type females to hemizygous males. The foundation and expansion colonies are maintained through continuous breeding of hemizygous males to wild type C57BL/6NTac females. The strain is considered fully congenic to C57BL/6NTac. In the production colony, wild type C57BL/6NTac animals are bred to hemizygous animals on the C57BL/6NTac background to produce hemizygous pups. In addition, another production colony is breeding BALB/cAnNTac females with hemizygous males on the C57BL/6NTac background to produce hemizygous CB6F1 pups, which are sold under model #9662.

2025 Pricing Guide Now Available

Get your Taconic Biosciences 2025 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.

Get Your Guide
Pricing Guide